For CD79B, irrespective of MYD88 mutational status, mutations were found in 4/28 (14%) of ENT lymphomas, 2/26 (8%) of CNS lymphomas, 2/7 (28%) of lymphoma of the testis, 1/8 (12%) of bone lymphomas, 1/2 (50%) of lymphomas located in the spleen, and 1/16 (6%) of skin lymphomas. Here, MYD88 is linked to lymphoma.